Vaccine development for respiratory syncytial virus

Current Opinion in Virology
Barney S Graham

Abstract

Respiratory syncytial virus (RSV) is an important and ubiquitous respiratory pathogen for which no vaccine is available notwithstanding more than 50 years of effort. It causes the most severe disease at the extremes of age and in settings of immunodeficiency. Although RSV is susceptible to neutralizing antibody, it has evolved multiple mechanisms of immune evasion allowing it to repeatedly infect people despite relatively little genetic diversity. Recent breakthroughs in determining the structure and antigenic content of the fusion (F) glycoprotein in its metastable untriggered prefusion form (pre-F) and the stable rearranged postfusion form (post-F) have yielded vaccine strategies that can induce potent neutralizing antibody responses and effectively boost pre-existing neutralizing activity. In parallel, novel live-attenuated and chimeric virus vaccine candidates and other novel approaches to deliver vaccine antigens have been developed. These events and activities have aroused optimism and a robust pipeline of potential vaccine products that promise to provide a means to reduce the public health burden of RSV infection.

Citations

Nov 14, 2017·Viral Immunology·Stanley A Plotkin
Sep 25, 2018·Journal of Clinical Pharmacology·Paul Ndaya-OlooJan Bonhoeffer
Apr 23, 2019·Expert Review of Vaccines·Indranil SarkarSylvia van Drunen Littel-van den Hurk
Jul 7, 2020·International Journal of Molecular Medicine·Ioannis N MammasDemetrios A Spandidos
Aug 22, 2020·The Journal of Infectious Diseases·Michiel van BovenUNKNOWN RESCEU Investigators
Sep 12, 2019·BMJ : British Medical Journal·Hannah H Nam, Michael G Ison
Jun 8, 2018·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Sara A TalebHadi M Yassine
Aug 4, 2020·Antiviral Chemistry & Chemotherapy·Elena Margret ThornhillDavid Verhoeven
Apr 20, 2018·Frontiers in Immunology·Elizabeth WhittakerOfer Levy
Mar 1, 2019·Vaccines·Emily PhungTracy J Ruckwardt
Oct 28, 2019·Frontiers in Immunology·Lydia J AthertonRalph A Tripp
Oct 30, 2019·Annals of the New York Academy of Sciences·Jennifer CableRino Rappuoli
Jan 9, 2019·Frontiers in Immunology·David J MorganTracy Hussell
Jun 8, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Devi RajanLarry J Anderson
Feb 7, 2019·Nature Reviews. Microbiology·Michael B Battles, Jason S McLellan
Sep 30, 2020·Vaccines·Kali F Crofts, Martha A Alexander-Miller
Jun 13, 2020·Mucosal Immunology·Stephen J Gurczynski, Bethany B Moore
Aug 20, 2019·The Pediatric Infectious Disease Journal·Matthew B JalinkPantelis Andreou
Sep 11, 2019·Vaccines·Ralph A Tripp, Ultan F Power
Dec 23, 2020·The Journal of Infectious Diseases·Emilia ThomasTerho Heikkinen
Dec 30, 2020·Microorganisms·Sonia BianchiniSusanna Esposito
Mar 12, 2021·Cell Host & Microbe·Rogier W Sanders, John P Moore
Jun 7, 2020·The Journal of Infection·Aharona Glatman-FreedmanZiona Haklai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antigenic Modulation

Antigenic modulation occurs when an antibody cross-links antigens on a cell surface, causing the antigens to become internalized. This can lead to therapeutic failure of monoclonal antibodies as the expression of the antigen becomes decreased on target cells. Find the latest research on antigenic modulation here.